ImmunoGen announces senior management promotions
This article was originally published in Scrip
ImmunoGen (US), a biotechnology company developing targeted anticancer products, has promoted Daniel Junius from executive vice-president and chief financial officer to president and chief operating officer. Dr John Lambert has been named executive vice-president of R&D and will continue as ImmunoGen's chief scientific officer.
You may also be interested in...
AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.